tiprankstipranks
Trending News
More News >
Clearside Biomedical (CLSD)
NASDAQ:CLSD
Advertisement

Clearside Biomedical (CLSD) AI Stock Analysis

Compare
1,042 Followers

Top Page

CLSD

Clearside Biomedical

(NASDAQ:CLSD)

Rating:43Neutral
Price Target:
$0.50
▲(0.00%Upside)
Clearside Biomedical's overall stock score is heavily impacted by its poor financial performance and challenging valuation. The bearish technical indicators and uncertain corporate restructuring efforts further contribute to a low score. The company's strategic initiatives may offer potential upside, but the risks remain significant.
Positive Factors
Clinical Trial Results
The Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results, maintaining stable BCVA and CST from baseline to Week 36.
Partnerships and Collaborations
CLSD has several partnership programs in place, ensuring continuity of support for the SCS microinjector platform.
Product Pipeline
CLSD has a commercially validated SCS platform and a competitive durable TKI asset for wet AMD that merits Ph3 investigation.
Negative Factors
Funding Challenges
Management cited challenging fundraising conditions, and the company has not been able to secure capital to fund the Phase 3 program of CLS-AX in wet AMD.
Operational Changes
All internal research and development programs will pause during this process, and employees will transition into consulting roles.
Strategic Uncertainty
CLSD's decision to explore strategic alternatives is disappointing given the company's phase 3 ready-asset (CLS-AX) for wAMD demonstrated the potential for flexible dosing.

Clearside Biomedical (CLSD) vs. SPDR S&P 500 ETF (SPY)

Clearside Biomedical Business Overview & Revenue Model

Company DescriptionClearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies to treat serious eye diseases. The company specializes in utilizing its proprietary SCS Microinjector™, which allows for the precise delivery of therapeutic agents to the suprachoroidal space of the eye. This technology is designed to improve the effectiveness and safety of treatments for retinal diseases. Clearside's core pipeline includes product candidates targeting conditions such as uveitis, diabetic macular edema, and retinal vein occlusion.
How the Company Makes MoneyClearside Biomedical makes money primarily through the development and potential commercialization of its proprietary therapies for eye diseases. The company generates revenue through collaborative agreements, licensing arrangements, and milestone payments from partnerships with pharmaceutical companies. These partnerships often involve Clearside providing its SCS Microinjector™ technology to facilitate drug delivery. Additionally, the company may earn revenue from the eventual sale of approved therapies derived from its product pipeline, as well as from potential royalties on sales of partnered products.

Clearside Biomedical Earnings Call Summary

Earnings Call Date:May 14, 2025
(Q4-2024)
|
% Change Since: -41.18%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in clinical trials and regulatory approvals, particularly in the Asia-Pacific region. However, the company faces challenges in securing funding for its Phase 3 program, which is crucial for its future success. The sentiment is positive due to the strong trial results and strategic partnerships, despite the funding and enrollment challenges.
Q4-2024 Updates
Positive Updates
Positive Results from ODYSSEY Phase 2b Trial
Clearside's ODYSSEY Phase 2b wet AMD clinical trial showed positive results, leading to a successful end of Phase 2 meeting with the FDA. The company is aligned on a pivotal Phase 3 program for CLS-AX, setting it up for potential commercial success.
Regulatory Progress and Partnerships in Asia-Pacific
Arctic Vision achieved several regulatory milestones in the Asia-Pacific region with ARCATUS/XIPERE, including approval in Australia and Singapore and a new drug application under review in China. A commercial collaboration with Santen Pharmaceuticals was also established.
Strong Financial Position
As of December 31, 2024, the company had cash and cash equivalents totaling approximately $20 million, with resources to fund operations into the fourth quarter of 2025.
Negative Updates
Funding Required for Phase 3 Program
Clearside is actively pursuing options to fund the CLS-AX Phase 3 program, indicating the need for additional financial resources or partnerships to commence the trial.
Potential Enrollment Challenges
The Phase 3 trial design for CLS-AX includes specific criteria that may exclude patients with high variability, which might affect enrollment speed.
Company Guidance
During the Clearside Biomedical Fourth Quarter 2024 Financial Results and Corporate Update Call, the company provided detailed guidance on its Phase 3 plans for the CLS-AX treatment for wet AMD. The pivotal Phase 3 program will consist of two non-inferiority trials, aiming to enroll treatment-naive patients, with a planned duration of enrollment of around 12 months. The design includes a personalized treatment interval (PTI) assessment at weeks 12, 16, and 20 to determine dosing regimens of every 12, 16, 20, or 24 weeks. The trials will use advanced OCT biomarkers to guide redosing, with an emphasis on reducing variability by excluding participants with significant non-disease-related visual acuity changes prior to randomization. The total cost of the trials is estimated at $55-$60 million each, with Clearside actively exploring funding options, including potential partnerships. The company also highlighted its strategic focus on suprachoroidal delivery, with ongoing collaborations and a robust pipeline, despite reporting cash and cash equivalents of approximately $20 million as of December 31, 2024.

Clearside Biomedical Financial Statement Overview

Summary
Clearside Biomedical faces significant financial challenges, with zero revenue and persistent losses. Negative equity and reliance on external finance indicate severe financial instability.
Income Statement
25
Negative
The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.
Balance Sheet
20
Very Negative
The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.
Cash Flow
30
Negative
The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.66M8.23M1.33M29.57M7.89M
Gross Profit1.51M7.87M1.12M29.40M7.89M
EBITDA-24.35M-23.06M-29.46M-449.00K-17.93M
Net Income-34.35M-32.48M-34.07M376.00K-18.03M
Balance Sheet
Total Assets25.13M34.02M51.30M42.90M19.32M
Cash, Cash Equivalents and Short-Term Investments20.02M28.92M48.26M30.44M17.29M
Total Debt703.00K43.00M1.28M675.00K1.98M
Total Liabilities63.98M49.93M40.70M4.93M10.56M
Stockholders Equity-38.85M-15.91M10.61M37.98M8.76M
Cash Flow
Free Cash Flow-25.68M-19.91M-13.61M-10.73M-13.18M
Operating Cash Flow-24.70M-18.14M-13.37M-10.73M-13.12M
Investing Cash Flow-638.00K-1.78M-246.00K0.00-55.00K
Financing Cash Flow16.44M414.00K31.33M23.78M7.87M

Clearside Biomedical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.50
Price Trends
50DMA
0.77
Negative
100DMA
0.83
Negative
200DMA
0.93
Negative
Market Momentum
MACD
-0.09
Positive
RSI
36.93
Neutral
STOCH
42.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.77, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 36.93 is Neutral, neither overbought nor oversold. The STOCH value of 42.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Risk Analysis

Clearside Biomedical disclosed 69 risk factors in its most recent earnings report. Clearside Biomedical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clearside Biomedical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (66)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
CHF27.37B16.739.37%1.98%28.68%7.54%
44
Neutral
$93.75M-55.14%-99.43%-69.40%
44
Neutral
$94.17M-122.69%20.91%
44
Neutral
$56.40M-127.99%37.54%
43
Neutral
$38.64M91.63%-55.47%24.92%
35
Underperform
$47.32M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLSD
Clearside Biomedical
0.50
-0.67
-57.26%
ADVM
Adverum Biotechnologies
2.70
-4.86
-64.29%
JSPR
Jasper Therapeutics
3.15
-17.06
-84.41%
ADAG
Adagene
1.99
-0.35
-14.96%
IVVD
Invivyd
0.78
-0.44
-36.07%

Clearside Biomedical Corporate Events

M&A TransactionsBusiness Operations and Strategy
Clearside Biomedical Explores Strategic Alternatives Amid Economic Challenges
Negative
Jul 17, 2025

On July 17, 2025, Clearside Biomedical announced it is exploring strategic alternatives to enhance shareholder value, including the sale or license of assets, partnerships, or mergers. To conserve resources, all employees, including top executives, will transition to consulting roles, and internal R&D programs will be paused. The company has retained Piper Sandler to assist in this strategic evaluation process. This move comes amid challenging economic conditions and aims to advance Clearside’s proprietary suprachoroidal delivery platform and ophthalmology pipeline. The workforce reduction is expected to incur charges of approximately $3.4 million in the third quarter of 2025.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Clearside Biomedical Approves Share Increase at Annual Meeting
Neutral
May 30, 2025

On May 30, 2025, Clearside Biomedical, Inc. held its annual meeting of stockholders where several key proposals were approved. The most significant outcome was the amendment to the company’s certificate of incorporation to increase the authorized shares of common stock from 200 million to 400 million, reflecting a strategic move to potentially expand its capital base. Additionally, the election of three directors, approval of executive compensation, and the ratification of Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025, were also confirmed.

The most recent analyst rating on (CLSD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Clearside Biomedical stock, see the CLSD Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025